Monoamine oxidase A (MAO-A) selectively targets the catalysts of the neurotransmitters of serotonin and norepinephrine and is a pharmacological target in seeking out beneficial agents for the treatment of depression [18]. The gene discussed is MAOA; the disease is depressive symptom measurement.